title: San-Huang-Xie-Xin-Tang extract suppresses hepatitis C virus replication and virus-induced cyclooxygenase-2 expression.
abstract: Chronic hepatitis C virus (HCV) infection is associated with chronic inflammation of liver, which leads to the development of cirrhosis and hepatocellular carcinoma (HCC). Because of severe side effects and only a 50-70% cure rate in genotype 1 HCV-infected patients upon current standard treatment with pegylated interferon-α plus ribavirin, new therapeutic regimens are still needed. San-Huang-Xie-Xin-Tang (SHXT) is a transitional Chinese herbal formula, composed of Rhei rhizoma, Scutellaria radix and Coptidis rhizome, and possesses anti-inflammatory effect. Here, we describe a (+)-catechin-containing fraction extracted from SHXT, referred as SHXT-frC, exhibited effective inhibition of HCV replication, with selectivity index value (SI; CC50 /EC50) of 84, and displayed synergistic anti-HCV effects when combined with interferon-α, HCV protease inhibitor telaprevir or polymerase inhibitor 2'-C-methylcytidine. The activation of factor-κB (NF-κB) and cyclooxygenase-2 (COX-2) signalling pathway has particular relevance to HCV-associated HCC. SHXT-frC treatment also caused a concentration-dependent decrease in the induction of COX-2 and NF-κB expression caused by either HCV replication or HCV NS5A protein. Collectively, SHXT-frC could be an adjuvant treatment for patients with HCV-induced liver diseases.
authors.affiliation: Department of Biotechnology, College of Life Science, Kaohsiung Medical University, Kaohsiung City, Taiwan, China. jclee@kmu.edu.tw
authors.forename: J C
authors.initials: JC
authors.lastname: Lee
authors.forename: C K
authors.initials: CK
authors.lastname: Tseng
authors.forename: S F
authors.initials: SF
authors.lastname: Wu
authors.forename: F R
authors.initials: FR
authors.lastname: Chang
authors.forename: C C
authors.initials: CC
authors.lastname: Chiu
authors.forename: Y C
authors.initials: YC
authors.lastname: Wu
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology; D002392:Catechin / Q000494:pharmacology; D002460:Cell Line; D051546:Cyclooxygenase 2 / Q000096:biosynthesis* / Q000235:genetics; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D003562:Cytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D016174:Hepacivirus / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D016328:NF-kappa B / Q000096:biosynthesis / Q000378:metabolism; D009842:Oligopeptides / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D017361:Viral Nonstructural Proteins / Q000378:metabolism; D014779:Virus Replication / Q000187:drug effects*; D012324:RNA-Dependent RNA Polymerase
chemical_list: D000998:Antiviral Agents; D002392:Catechin; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D003562:Cytidine; D004365:Drugs, Chinese Herbal; D016898:Interferon-alpha; D016328:NF-kappa B; D009842:Oligopeptides; D017361:Viral Nonstructural Proteins; C501029:San-Huang-Xie-Xin-Tang; C513402:2'-C-methylcytidine; C486464:telaprevir; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase